ArticleSurgery today2026
Chronological age does not predict poor outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a retrospective study.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe benefit of neoadjuvant chemoradiotherapy (NACRT) for elderly patients with locally advanced rectal cancer (LARC) remains unclear because these patients are often excluded from trials. We evaluated the safety and oncologic outcomes of NACRT in elderly LARC patients.
methodsThe subjects of this retrospective analysis were 98 LARC patients who underwent radical resection after NACRT. We compared patients aged ≥ 75 years (Elderly group) with non-elderly patients (non-Elderly group), assessing treatment completion, adverse events, pathological response, and survival outcomes. Prognostic factors for relapse-free survival (RFS) were examined using Cox regression.
resultsThe Elderly group patients had poorer performance status and more frequent chemotherapy dose reductions. The median relative dose intensity of chemotherapy did not differ significantly between the Elderly and non-Elderly groups, and the median relative dose intensity of radiotherapy was 100% in both groups. The incidence of grade ≥ 3 adverse events was comparable between the groups. RFS (P = 0.313) and cancer-specific survival (P = 0.408) did not differ significantly. Multivariate analysis identified the American Society of Anesthesiologists-performance status score 3 (HR: 4.64, P = 0.002), Clavien-Dindo grade ≥ 3 complications (HR: 2.72, P = 0.008), and ypN3 (HR: 2.96, P = 0.036), but not age, as independent predictors of RFS.
conclusionsChronological age did not affect toxicity, pathological response, or survival outcomes adversely. Thus, NACRT can be offered safely to elderly LARC patients with appropriate performance status, suggesting that age alone should not preclude curative treatment.
Indexed as
Identifiers
42216999What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.